Eli Lilly and Company (LLY) Earnings Call Transcripts
Eli Lilly and Company's Latest Earnings Call - September 14, 2026
In the third quarter of fiscal year 2026, Eli Lilly reported a strong performance driven by its obesity treatment portfolio, particularly Zepbound and Foundayo. Revenue reached $15.2 billion, exceeding expectations by $1.2 billion, while earnings per share (EPS) were $3.45, beating estimates by $0.25. Management maintained its full-year guidance, projecting revenue growth of 15% year-over-year, signaling confidence in continued market penetration and uptake of its obesity treatments.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $15.2B (beat) |
| EPS | $3.45 (beat) |
| Obesity Treatment Market Share | 30% (positive) |
| Medicare Bridge Program Uptake | 600,000 (positive) |
| Projected Revenue Growth | 15% (inline) |
| Trialists for Foundayo | 36,000+ (positive) |
Guidance from management
Management maintained its full-year revenue growth guidance of 15%, indicating confidence in the continued uptake of obesity treatments and pipeline advancements.
What management said
No, we-- I mean we have a network of more than 20 third-party providers that are actively having conversations with employers. We are -- our team is also having active conversations, and I believe we'll have a number of employers opt in or maintained coverage through this program.
For '27. Yes, because this is the cycle for typically, you make your benefits decisions around this time frame usually before October to announce what you're covering in the next year. So we anticipate a number of companies will enter through this space.
What analysts pressed on
Analysts expressed concerns about the stagnation in commercial coverage and the potential impact of generic semaglutide on market dynamics. There were also questions regarding the sustainability of the Medicare Bridge program post-2027.
Main topics on the call
- Obesity Treatment Portfolio Expansion — Eli Lilly's management emphasized their commitment to a broad obesity treatment portfolio, stating, "We believe that having those options are critical to meet patients where they are." The company is focusing on increasi...
- Medicare Bridge Program Uptake — The Medicare Bridge program has seen significant uptake, with approximately 600,000 people utilizing the program. Management noted, "We're seeing pretty significant uptake of number of people actually coming through Brid...
- Foundayo Launch Progress — Foundayo's launch is progressing well, with over 36,000 trialists and a growing market share of over 30% in new starts within the oral GLP-1 category. Management stated, "We're starting to see some progress, and that's a...
- Cost-Effectiveness Study Results — A recent cost-effectiveness study showed that Zepbound can yield savings of up to $600 per month per person after 12 months of treatment, which management believes will persuade employers to invest in obesity treatments....
Read the full Eli Lilly and Company transcript (September 14, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Eli Lilly and Company
Eli Lilly and Company (LLY) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on NYSE and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 109 calls on record spanning January 14, 2020 to September 14, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 109 Eli Lilly and Company earnings call transcripts on record, spanning January 14, 2020 to September 14, 2026. Based on this history, Eli Lilly and Company reports quarterly. The most recent call on file is dated September 14, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- LLY
- Exchange
- NYSE
- Country
- US
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 109
- First call
- January 14, 2020
- Most recent
- September 14, 2026
- Reporting cadence
- quarterly